- Insider Monkey•11 hours ago
Seattle Genetics, Inc. (NASDAQ:SGEN) just reported second quarter financials, and the company is up nearly 10% on the data. Alongside the numbers, however, we got word that the company is pitching to put out its phase III topline for Adcetris as a lymphoma candidate, before the close of this quarter. This has the potential to […]
- Zacks•2 days ago
Seattle Genetics (SGEN) reported a loss of 23 cents per share, narrower than both the Zacks Consensus Estimate of a loss of 33 cents.
Seattle Genetics, Inc.NasdaqGS
After hours: 47.370.00 (0.00%) as of 4:56 PM EDT
|Bid||41.10 x 100|
|Ask||52.01 x 200|
|52wk Range||26.02 - 49.66|
|Day's Range||46.75 - 47.94|
|Avg Vol (3m)||869,157|
As of 4:00 PM EDT. Market closed.